이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

1차(1L) 전이성 비편평 비소세포 폐암(NSCLC)에서 유지 관리 올라파립 또는 유지 관리 페메트렉시드와 함께 펨브롤리주맙에 대한 연구(MK-7339-006, KEYLYNK-006)

2026년 9월 3일 업데이트: Merck Sharp & Dohme LLC

전이성 비편평 비소세포폐암 참가자의 1차 치료에서 펨브롤리주맙과 페메트렉시드/백금(카르보플라틴 또는 시스플라틴)을 병용한 후 펨브롤리주맙 및 유지 관리 올라파립 대 유지 관리 페메트렉시드의 3상 연구

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

This study has 2 phases: an Induction Phase of up to ~4 Cycles (up to ~12 weeks [cycle =3 weeks]) and a Maintenance Phase of up to ~31 cycles of pembrolizumab (cycle = 3 weeks]); total pembrolizumab treatment duration will be up to ~35 cycles (up to ~2 years). In the Induction Phase, participants receive pembrolizumab plus pemetrexed plus platinum (carboplatin or cisplatin, at the investigator's discretion). In the Maintenance Phase, participants with a partial or complete disease response or with stable disease after completing four cycles of induction therapy and who meet eligibility criteria will be randomly assigned to receive pembrolizumab plus maintenance olaparib OR pembrolizumab plus maintenance pemetrexed. In the Maintenance Phase, participants receive pembrolizumab for up to 31 cycles (cycle = 3 weeks) plus maintenance olaparib OR maintenance pemetrexed until progressive disease (PD), intolerable toxicities, or physician decision.

Qualified participants in each study arm of the maintenance phase (Pembrolizumab plus Olaparib and Pembrolizumab plus Pemetrexed) who complete up to ~35 cycles of pembrolizumab (up to ~2 years [cycle =3 weeks]) may be eligible to receive a second course of pembrolizumab for up to ~17 cycles (up to ~1 additional year). Per protocol, response or progression during the second pembrolizumab course will not be counted towards patient reported outcomes (PROs) or efficacy outcome measures and adverse events during the second pembrolizumab course will not be counted towards safety outcome measures.

연구 유형

중재적

등록 (실제)

1003

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Wellington, 뉴질랜드, 6021
        • Capital & Coast District Health Board - Wellington Hospital ( Site 1101)
    • Manawatu-Wanganui
      • Palmerston North, Manawatu-Wanganui, 뉴질랜드, 4414
        • MidCentral DHB Palmerston North Hospital ( Site 1102)
      • Kaohsiung City, 대만, 833
        • Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0907)
      • Taichung, 대만, 40447
        • China Medical University Hospital ( Site 0904)
      • Tainan, 대만, 70457
        • National Cheng Kung University Hospital ( Site 0905)
      • Taipei, 대만, 104
        • Mackay Memorial Hospital ( Site 0902)
      • Taipei, 대만, 100
        • National Taiwan University Hospital ( Site 0900)
      • Taoyuan, 대만, 333
        • Chang Gung Medical Foundation.Linkou Branch ( Site 0903)
      • Seoul, 대한민국, 03080
        • Seoul National University Hospital ( Site 1000)
      • Seoul, 대한민국, 08308
        • Korea University Guro Hospital ( Site 1008)
    • Kyonggi-do
      • Goyang-si, Kyonggi-do, 대한민국, 10408
        • National Cancer Center ( Site 1006)
      • Suwon, Kyonggi-do, 대한민국, 16247
        • The Catholic University of Korea St. Vincent s Hospital ( Site 1003)
      • Suwon, Kyonggi-do, 대한민국, 16499
        • Ajou University Hospital ( Site 1004)
    • Kyongsangnam-do
      • Jinju, Kyongsangnam-do, 대한민국, 52727
        • Gyeongsang National University Hospital ( Site 1005)
    • North Chungcheong
      • Cheongju-si, North Chungcheong, 대한민국, 28644
        • Chungbuk National University Hospital ( Site 1002)
    • Seoul
      • Songpa-gu, Seoul, 대한민국, 05505
        • Asan Medical Center ( Site 1007)
      • Hamburg, 독일, 22087
        • Katholisches Marienkrankenhaus gGmbH ( Site 1522)
    • Bavaria
      • Aschaffenburg, Bavaria, 독일, 63739
        • Studienzentrum Aschaffenburg ( Site 1525)
      • Munich, Bavaria, 독일, 80336
        • Klinikum der LMU ( Site 1500)
      • Munich, Bavaria, 독일, 81925
        • Klinikum Bogenhausen Staedt. Klinikum Muenchen GmbH ( Site 1523)
      • Regensburg, Bavaria, 독일, 93053
        • Universitaetsklinikum Regensburg ( Site 1512)
      • Würzburg, Bavaria, 독일, 97074
        • Klinikum Wuerzburg Mitte gGmbH ( Site 1509)
    • Hesse
      • Frankfurt am Main, Hesse, 독일, 60590
        • Universitaetsklinikum Frankfurt ( Site 1513)
      • Immenhausen, Hesse, 독일, 34376
        • Pneumologische Lehrklinik Universitaet Goettingen ( Site 1501)
    • Lower Saxony
      • Göttingen, Lower Saxony, 독일, 37075
        • Universitaetsmedizin Goettingen ( Site 1507)
    • North Rhine-Westphalia
      • Bonn, North Rhine-Westphalia, 독일, 53127
        • Universitaetsklinikum Bonn ( Site 1524)
      • Essen, North Rhine-Westphalia, 독일, 45136
        • Kliniken Essen Mitte ( Site 1517)
    • Rhineland-Palatinate
      • Koblenz, Rhineland-Palatinate, 독일, 56068
        • InVo-Institut fuer Versorgungsforschung in der Onkologie ( Site 1514)
    • Thuringia
      • Erfurt, Thuringia, 독일, 99089
        • Helios Klinikum Erfurt GmbH ( Site 1502)
    • Moscow
      • Moscow, Moscow, 러시아 제국, 115478
        • Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 2000)
      • Moscow, Moscow, 러시아 제국, 119991
        • First Moscow State Medical University n.a. I.M.Sechenov ( Site 2024)
      • Moscow, Moscow, 러시아 제국, 125284
        • Moscow Research Oncology Institute named after P.A. Hertsen ( Site 2009)
      • Moscow, Moscow, 러시아 제국, 125367
        • FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 2006)
    • Moscow Oblast
      • Balashikha, Moscow Oblast, 러시아 제국, 143900
        • Moscow Regional Oncological Dispensary ( Site 2028)
    • Nizhny Novgorod Oblast
      • Nizhny Novgorod, Nizhny Novgorod Oblast, 러시아 제국, 603081
        • Nizhniy Novgorod Region Oncology Dispensary ( Site 2026)
    • Omsk Oblast
      • Omsk, Omsk Oblast, 러시아 제국, 644013
        • Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site 2010)
    • Samara Oblast
      • Samara, Samara Oblast, 러시아 제국, 443031
        • SBHI Samara Regional Clinical Oncology Dispensary ( Site 2016)
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 194291
        • SBHI Leningrad Regional Clinical Hospital ( Site 2002)
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 195271
        • SPb Central Clinical Railway Hospital ( Site 2003)
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 197758
        • National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 2004)
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 198255
        • SPb SBHI City Clinical Oncological Dispensary ( Site 2001)
    • Tatarstan, Respublika
      • Kazan', Tatarstan, Respublika, 러시아 제국, 420029
        • Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 2021)
      • Brasov, 루마니아, 500152
        • Spitalul PDR Medlife ( Site 2509)
    • Bucharest
      • Bucharest, Bucharest, 루마니아, 013823
        • MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 2502)
    • Cluj
      • Cluj-Napoca, Cluj, 루마니아, 407280
        • S.C. Radiotherapy Center Cluj S.R.L ( Site 2507)
      • Cluj-Napoca, Cluj, 루마니아, 400015
        • Cardiomed SRL Cluj-Napoca ( Site 2504)
    • Constanța County
      • Ovidiu, Constanța County, 루마니아, 905900
        • Ovidius Clinical Hospital OCH ( Site 2501)
    • Dolj
      • Craiova, Dolj, 루마니아, 200542
        • S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2508)
    • Timiș County
      • Timișoara, Timiș County, 루마니아, 300239
        • Policlinica Oncomed SRL ( Site 2505)
    • Alabama
      • Birmingham, Alabama, 미국, 35205
        • Alabama Oncology Bruno Cancer Center ( Site 0001)
      • Muscle Shoals, Alabama, 미국, 35661
        • Northwest Alabama Cancer Center, PC ( Site 0002)
    • California
      • Burbank, California, 미국, 91505
        • Disney Family Cancer Center ( Site 0005)
    • Florida
      • Boca Raton, Florida, 미국, 33486
        • Boca Raton Regional Hospital ( Site 0018)
      • Orange City, Florida, 미국, 32763
        • Mid-Florida Cancer Centers ( Site 0022)
      • Tampa, Florida, 미국, 33612
        • Moffitt Cancer Center ( Site 0024)
    • Georgia
      • Columbus, Georgia, 미국, 31904
        • Columbus Regional Research Institute ( Site 0098)
    • Illinois
      • Chicago, Illinois, 미국, 60608
        • Mount Sinai Hospital Medical Center ( Site 0032)
      • Rolling Meadows, Illinois, 미국, 60008
        • Oncology of Northshore ( Site 0033)
    • Indiana
      • Merrillville, Indiana, 미국, 46410
        • Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0036)
    • Maryland
      • Baltimore, Maryland, 미국, 21239
        • Medstar Good Samaritan Hospital ( Site 0040)
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • Barbara Ann Karmanos Cancer Institute ( Site 0041)
    • Mississippi
      • Hattiesburg, Mississippi, 미국, 39401
        • Hattiesburg Clinic ( Site 0045)
    • Montana
      • Billings, Montana, 미국, 59102
        • Frontier Oncology ( Site 0080)
      • Bozeman, Montana, 미국, 59715
        • Bozeman Health Deaconness Cancer Center ( Site 0046)
    • North Carolina
      • Cary, North Carolina, 미국, 27518
        • Waverly Hematology Oncology ( Site 0081)
    • Tennessee
      • Knoxville, Tennessee, 미국, 37920
        • University of Tennessee Medical Center Knoxville ( Site 0060)
      • Knoxville, Tennessee, 미국, 37916
        • Thompson Cancer Survival Center ( Site 2812)
    • Texas
      • The Woodlands, Texas, 미국, 77380
        • Renovatio Clinical ( Site 0062)
    • Washington
      • Spokane Valley, Washington, 미국, 99216
        • Cancer Care Northwest ( Site 0071)
      • Rio de Janeiro, 브라질, 20231-050
        • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0203)
      • São Paulo, 브라질, 01246-000
        • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0200)
      • São Paulo, 브라질, 01321-001
        • BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0214)
      • São Paulo, 브라질, 01321-001
        • Hospital Paulistano - Amil Clinical Research ( Site 0207)
    • Ceará
      • Fortaleza, Ceará, 브라질, 60351-030
        • Instituto do Cancer do Ceara ( Site 0201)
    • Estado de Bahia
      • Salvador, Estado de Bahia, 브라질, 41253-190
        • Hospital Sao Rafael ( Site 0212)
    • Pará
      • Belém, Pará, 브라질, 66053-000
        • Oncologica do Brasil ( Site 0210)
    • Rio Grande do Sul
      • Bento Gonçalves, Rio Grande do Sul, 브라질, 95700-000
        • Hospital Tacchini ( Site 0208)
      • Porto Alegre, Rio Grande do Sul, 브라질, 90050-170
        • Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 0209)
      • Santa Cruz do Sul, Rio Grande do Sul, 브라질, 96810-110
        • Saint Gallen Instituto de Oncologia ( Site 0206)
    • Santa Catarina
      • Florianópolis, Santa Catarina, 브라질, 88020-210
        • YNOVA Pesquisa Clinica ( Site 0215)
      • Itajaí, Santa Catarina, 브라질, 88301-220
        • Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0202)
      • Joinville, Santa Catarina, 브라질, 89201-260
        • Centro de Hematologia e Oncologia ( Site 0205)
    • São Paulo
      • Sao Jose Rio Preto, São Paulo, 브라질, 15080-000
        • Hospital de Base de Sao Jose de Rio Preto ( Site 0204)
      • Barcelona, 스페인, 08003
        • Hospital del Mar ( Site 1702)
      • Seville, 스페인, 41014
        • Hospital Universitario Nuestra Senora de Valme ( Site 1703)
      • Zaragoza, 스페인, 50009
        • Hospital Clinico Lozano Blesa ( Site 1700)
    • Madrid
      • Pozuelo de Alarcón, Madrid, 스페인, 28223
        • Hospital Universitario Quiron Madrid ( Site 1701)
    • Valenciana, Comunitat
      • Valencia, Valenciana, Comunitat, 스페인, 46010
        • Hospital Clinico Universitario de Valencia ( Site 1706)
      • Córdoba, 아르헨티나, X5004SHP
        • Clínica Universitaria Reina Fabiola ( Site 0505)
      • Santa Fe, 아르헨티나, S3000AOL
        • Sanatorio Privado San Geronimo S.R.L ( Site 0510)
    • Buenos Aires
      • Bahía Blanca, Buenos Aires, 아르헨티나, B8001HXM
        • Hospital Italiano Regional del Sur ( Site 0509)
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, 아르헨티나, C1199ABB
        • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0511)
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, 아르헨티나, C1280AEB
        • Hospital Britanico de Buenos Aires ( Site 0500)
    • Córdoba Province
      • Río Cuarto, Córdoba Province, 아르헨티나, X5800AEV
        • Instituto Medico Rio Cuarto ( Site 0501)
    • Santa Fe Province
      • Rosario, Santa Fe Province, 아르헨티나, S2000KZE
        • Centro Oncológico de Rosario ( Site 0507)
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, 아르헨티나, T4000IAK
        • Centro Medico San Roque ( Site 0506)
      • Birmingham, 영국, B9 5SS
        • Birmingham Heartlands Hospital ( Site 1910)
    • London, City of
      • London, London, City of, 영국, EC1M 6BQ
        • Barts Health NHS Trust - St Bartholomew s Hospital ( Site 1923)
      • London, London, City of, 영국, SW10 9NH
        • Chelsea and Westminster Hospital ( Site 1901)
    • Suffolk
      • Bury St Edmunds, Suffolk, 영국, IP33 2QZ
        • West Suffolk Hospitals NHS Trust ( Site 1919)
    • United Kingdom
      • Edinburgh, United Kingdom, 영국, EH4 2XU
        • Western General Hospital, Edinburgh ( Site 1924)
    • Wales
      • Swansea, Wales, 영국, SA2 8QA
        • Singleton Hospital ( Site 1909)
    • Worcestershire
      • Colchester, Worcestershire, 영국, CO4 5JL
        • Colchester General Hospital ( Site 1911)
      • Vienna, 오스트리아, 1210
        • Krankenhaus Nord - Klinik Floridsdorf ( Site 1300)
    • State of Vienna
      • Vienna, State of Vienna, 오스트리아, 1145
        • Social Medical Center - Otto Wagner Hospital ( Site 1301)
    • Tyrol
      • Innsbruck, Tyrol, 오스트리아, 6020
        • Innsbruck LKH ( Site 1302)
    • Upper Austria
      • Linz, Upper Austria, 오스트리아, 4020
        • Ordensklinikum Linz GmbH Elisabethinen ( Site 1307)
      • Wels, Upper Austria, 오스트리아, 4600
        • Klinikum Wels-Grieskirchen ( Site 1304)
      • Kyiv, 우크라이나, 03115
        • Kyiv City Clinical Oncology Centre ( Site 2210)
    • Cherkasy Oblast
      • Cherkasy, Cherkasy Oblast, 우크라이나, 18009
        • Cherkasy Regional Oncology Dispensary ( Site 2211)
    • Dnipropetrovsk Oblast
      • Dnipro, Dnipropetrovsk Oblast, 우크라이나, 49102
        • Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 2201)
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk, Ivano-Frankivsk Oblast, 우크라이나, 76018
        • MI Precarpathian Clinical Oncology Center ( Site 2204)
    • Kharkiv Oblast
      • Kharkiv, Kharkiv Oblast, 우크라이나, 61024
        • Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2212)
      • Kharkiv, Kharkiv Oblast, 우크라이나, 61070
        • CNPE "Regional Center of Oncology"-Thoracic organs ( Site 2205)
    • Kirovohrad Oblast
      • Kropyvnitskiy, Kirovohrad Oblast, 우크라이나, 25006
        • PP PPC Acinus Medical and Diagnostic Centre ( Site 2209)
    • Kyivska Oblast
      • Khodosovka, Kyivska Oblast, 우크라이나, 08173
        • Medical Center Asklepion LLC ( Site 2234)
      • Kyiv, Kyivska Oblast, 우크라이나, 03126
        • Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2213)
      • Kyiv, Kyivska Oblast, 우크라이나, 03039
        • Medical Center Verum ( Site 2230)
    • Odesa Oblast
      • Odesa, Odesa Oblast, 우크라이나, 65055
        • MI Odessa Regional Oncological Centre ( Site 2208)
    • Zakarpattia Oblast
      • Uzhhorod, Zakarpattia Oblast, 우크라이나, 88000
        • Central City Clinical Hospital ( Site 2207)
      • Fukuoka, 일본, 8108563
        • National Hospital Organization Kyushu Medical Center ( Site 0805)
      • Niigata, 일본, 951-8566
        • Niigata Cancer Center Hospital ( Site 0808)
      • Okayama, 일본, 700-8558
        • Okayama University Hospital ( Site 0810)
      • Osaka, 일본, 541-8567
        • Osaka International Cancer Institute ( Site 0809)
      • Tokyo, 일본, 135-8550
        • Cancer Institute Hospital of JFCR ( Site 0800)
    • Aichi-ken
      • Nagoya, Aichi-ken, 일본, 460-0001
        • National Hospital Organization Nagoya Medical Center ( Site 0806)
      • Nagoya, Aichi-ken, 일본, 464-8681
        • Aichi Cancer Center ( Site 0803)
    • Chiba
      • Kashiwa, Chiba, 일본, 2778577
        • National Cancer Center Hospital East ( Site 0801)
    • Ishikawa-ken
      • Kanazawa, Ishikawa-ken, 일본, 920-8641
        • Kanazawa University Hospital ( Site 0811)
    • Kanagawa
      • Yokohama, Kanagawa, 일본, 241-8515
        • Kanagawa Cancer Center ( Site 0807)
    • Miyagi
      • Sendai, Miyagi, 일본, 981-0914
        • Sendai Kousei Hospital ( Site 0812)
    • Osaka
      • Hirakata, Osaka, 일본, 573-1191
        • Kansai Medical University Hospital ( Site 0804)
      • Sakai, Osaka, 일본, 591-8555
        • National Hospital Organization Kinki-chuo Chest Medical Center ( Site 0813)
    • Shizuoka
      • Suntogun, Shizuoka, 일본, 411-8777
        • Shizuoka Cancer Center ( Site 0802)
    • British Columbia
      • North Vancouver, British Columbia, 캐나다, V7L 2L7
        • Lions Gate Hospital ( Site 0106)
      • Victoria, British Columbia, 캐나다, V8R 6V5
        • BC Cancer - Victoria ( Site 0109)
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다, B3H 2Y9
        • Queen Elizabeth II Health Sciences Centre ( Site 0107)
    • Ontario
      • Greater Sudbury, Ontario, 캐나다, P3E 5J1
        • Health Sciences North Research Institute ( Site 0115)
      • Kitchener, Ontario, 캐나다, N2G 1G3
        • Waterloo Regional Health Network (WRHN) ( Site 0117)
      • Newmarket, Ontario, 캐나다, L3Y 2P9
        • Stronach Regional Cancer Centre ( Site 0101)
    • Quebec
      • Greenfield Park, Quebec, 캐나다, J4V 2H1
        • CISSS de la Monteregie-Centre ( Site 0114)
      • Montreal, Quebec, 캐나다, H3T 1M5
        • CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0110)
      • Montreal, Quebec, 캐나다, H2X 3E4
        • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0105)
      • Rimouski, Quebec, 캐나다, G5L 5T1
        • Centre de Sante et des Services Sociaux de Rimouski-Neigette ( Site 0104)
      • Sherbrooke, Quebec, 캐나다, J1H 5N4
        • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0103)
    • Antioquia
      • Medellín, Antioquia, 콜롬비아, 050030
        • Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0604)
    • Atlántico
      • Barranquilla, Atlántico, 콜롬비아, 080020
        • Clinica de la Costa S.A.S. ( Site 0608)
    • Bogota D.C.
      • Bogotá, Bogota D.C., 콜롬비아, 110221
        • Administradora Country S.A. ( Site 0603)
      • Bogotá, Bogota D.C., 콜롬비아, 111321
        • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 0601)
      • Adana, 터키 (Türkiye), 01120
        • Baskent Unv. Adana Uyg. ve Arast. Hastanesi ( Site 2101)
      • Ankara, 터키 (Türkiye), 06500
        • Gazi Universitesi Tip Fakultesi ( Site 2104)
      • Ankara, 터키 (Türkiye), 06800
        • Ankara Bilkent Sehir Hastanesi ( Site 2105)
      • Istanbul, 터키 (Türkiye), 34093
        • Bezmialem Vakif Univ. Tıp Fakultesi Hastanesi Tibbi Onkoloji Bolumu ( Site 2107)
      • Istanbul, 터키 (Türkiye), 34722
        • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2103)
      • Izmir, 터키 (Türkiye), 35040
        • Ege Universitesi Tip Fakultesi ( Site 2109)
      • Kayseri, 터키 (Türkiye), 38039
        • Erciyes Universitesi Tip Fakultesi ( Site 2108)
      • Samsun, 터키 (Türkiye), 55139
        • Ondokuz Mayıs Universitesi-Oncology department ( Site 2106)
    • Tekirdas
      • Tekirdağ, Tekirdas, 터키 (Türkiye), 59100
        • Namik Kemal Universitesi Tip Fakultesi ( Site 2100)
    • Greater Poland Voivodeship
      • Konin, Greater Poland Voivodeship, 폴란드, 62-500
        • Przychodnia Lekarska Komed ( Site 2416)
      • Poznan, Greater Poland Voivodeship, 폴란드, 61-693
        • MED-POLONIA Sp. z o.o. ( Site 2419)
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, 폴란드, 31-202
        • Krakowski Szpital Specjalistyczny im Jana Pawla II ( Site 2420)
    • Lower Silesian Voivodeship
      • Zgorzelec, Lower Silesian Voivodeship, 폴란드, 59-900
        • Wielospecjalistyczny Szpital SPZOZ w Zgorzelcu ( Site 2404)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2418)
    • Silesian Voivodeship
      • Racibórz, Silesian Voivodeship, 폴란드, 47-400
        • Szpital Rejonowy im. dr Jozefa Rostka ( Site 2402)
    • Warmian-Masurian Voivodeship
      • Olsztyn, Warmian-Masurian Voivodeship, 폴란드, 10-357
        • Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie ( Site 2417)
    • Ain
      • Vandœuvre-lès-Nancy, Ain, 프랑스, 54519
        • Institut De Cancerologie De Lorraine ( Site 1409)
    • Aisne
      • Chauny, Aisne, 프랑스, 02300
        • Centre Hospitalier De Chauny ( Site 1411)
    • Calvados
      • Caen, Calvados, 프랑스, 14033
        • CHU Caen ( Site 1406)
    • Maine-et-Loire
      • Angers, Maine-et-Loire, 프랑스, 49100
        • CHU Angers ( Site 1405)
    • Moselle
      • Vantoux, Moselle, 프랑스, 57070
        • Hopital Robert Schuman ( Site 1402)
    • Puy-de-Dome
      • Clermont-Ferrand, Puy-de-Dome, 프랑스, 63011
        • Centre Jean Perrin ( Site 1407)
    • Pyrenees-Atlantiques
      • Pau, Pyrenees-Atlantiques, 프랑스, 64000
        • Centre Hospitalier de Pau ( Site 1412)
    • Seine-Maritime
      • Rouen, Seine-Maritime, 프랑스, 76000
        • CHU de Rouen ( Site 1403)
    • Val-de-Marne
      • Saint-Mandé, Val-de-Marne, 프랑스, 94163
        • Hopital d'Instruction des Armees Begin ( Site 1413)
    • New South Wales
      • Liverpool, New South Wales, 호주, 2170
        • Liverpool Hospital ( Site 1201)
      • Wollongong, New South Wales, 호주, 2500
        • Southern Medical Day Care Centre ( Site 1200)
    • Queensland
      • Townsville, Queensland, 호주, 4814
        • Townsville General Hospital ( Site 1202)
    • Victoria
      • Clayton, Victoria, 호주, 3168
        • Monash Cancer Centre ( Site 1205)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Have a histologically or cytologically confirmed diagnosis nonsquamous NSCLC.

  2. Have stage IV nonsquamous NSCLC.

  3. Have confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or Proto-oncogene tyrosine-protein kinase (ROS1)-directed therapy is not indicated.

  4. Have measurable disease based on RECIST 1.1.

  5. Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated.

    Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase. Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time.

  6. Have a life expectancy of at least 3 months.

  7. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status assessed within 7 days prior to the administration of study intervention.

  8. Have not received prior systemic treatment for their advanced/metastatic NSCLC.

  9. Have adequate organ function.

  10. Male and female participants who are not pregnant and of childbearing potential must follow contraceptive guidance during the treatment period and for 180 days afterwards.

  11. Male participants must refrain from donating sperm, and female participants must refrain from donating eggs to others or freeze/store for her own use during the treatment period and for 180 days afterwards.

Exclusion Criteria:

  1. Has predominantly squamous cell histology NSCLC.
  2. Has a known additional malignancy that is progressing or has progressed within the past 3 years requiring active treatment.
  3. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  4. Has a severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
  5. Has a known hypersensitivity to any components or excipients of cisplatin, carboplatin, pemetrexed, or olaparib.
  6. Has an active autoimmune disease that has required systemic treatment in past 2 years.
  7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
  8. Has a known history of human immunodeficiency virus (HIV) infection, a known history of hepatitis B infection, or known active hepatitis C virus infection.
  9. Has interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment.
  10. Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor.
  11. Has received prior therapy with an agent directed to programmed cell death ligand 1 (PD-L1), anti PD-L2, or directed to a stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
  12. Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
  13. Has completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib

For the Induction Phase, participants receive 4 cycles (up to ~12 weeks [cycle = 3 weeks]): pembrolizumab 200 mg intravenous (IV) on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of each cycle (Cycles 1 through 4).

If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. The participant can continue to receive maintenance olaparib until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to ~35 cycles (up to ~2 years [cycle = 3 weeks]).

IV infusion

다른 이름들:
  • MK-3475
  • 키트루다®

Oral Tablet

다른 이름들:
  • 린파자®

IV infusion

다른 이름들:
  • 플래티놀®
  • PLATINOL®-AQ

IV infusion

다른 이름들:
  • 파라플라틴®

IV infusion

다른 이름들:
  • 알림타®
활성 비교기: Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed

For the Induction Phase, participants receive 4 cycles (up to ~12 weeks [cycle = 3 weeks]): pembrolizumab 200 mg IV on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin AUC 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of each cycle (Cycles 1 through 4).

If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance pemetrexed 500 mg/m^2 IV on Day 1 of each 3-week cycle. The participant can continue to receive maintenance pemetrexed until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to ~35 cycles (up to ~2 years [cycle = 3 weeks]).

IV infusion

다른 이름들:
  • MK-3475
  • 키트루다®

IV infusion

다른 이름들:
  • 플래티놀®
  • PLATINOL®-AQ

IV infusion

다른 이름들:
  • 파라플라틴®

IV infusion

다른 이름들:
  • 알림타®

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-free Survival (PFS)
기간: Up to ~31 months

PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was analyzed by the non-parametric Kaplan-Meier (K-M) method. The protocol specified final analysis of PFS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~31 months
Overall Survival (OS)
기간: Up to ~51 months

OS was defined as the time from randomization to death due to any cause. OS was analyzed by the non-parametric K-M method. Participants without documented death at the time of analyses were censored at the date of last known to be alive. The protocol specified final analysis of OS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~51 months

2차 결과 측정

결과 측정
측정값 설명
기간
Number of Participants Who Experience One or More Adverse Events (AEs)
기간: Up to ~5 years

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.

Up to ~5 years
Number of Participants Who Discontinue Study Treatment Due to an AE
기간: Up to ~5 years

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.

Up to ~5 years
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 and 30) Scale Score
기간: Baseline and Week 24

EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
Time to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score
기간: Up to ~24 months

EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome was not done in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score
기간: Baseline and Week 24

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 cough (Item 1) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-LC13 Cough (Item 1) Scale Score
기간: Up to ~24 months

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 1). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
기간: Baseline and Week 24

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 chest pain (Item 10) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
기간: Up to ~24 months

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in chest pain (Item 10). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
기간: Baseline and Week 24

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
기간: Up to ~24 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
기간: Baseline and Week 24

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
기간: Up to ~24 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Medical Director, Merck Sharp & Dohme LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2019년 6월 28일

기본 완료 (실제)

2024년 2월 7일

연구 완료 (실제)

2026년 1월 30일

연구 등록 날짜

최초 제출

2019년 6월 3일

QC 기준을 충족하는 최초 제출

2019년 6월 3일

처음 게시됨 (실제)

2019년 6월 6일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 3일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 7339-006
  • 2018 (미국 NIH 보조금/계약)
  • MK-7339-006 (기타 식별자: MSD)
  • KEYLYNK-006 (기타 식별자: MSD)
  • 194895 (레지스트리 식별자: JAPIC-CTI)
  • 2018-004720-11 (EudraCT 번호)
  • U1111-1300-7107 (레지스트리 식별자: UTN)
  • 2023-509774-40-00 (레지스트리 식별자: EU CT)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .